Pearl River Capital’s AnaptysBio ANAB Stock Holding History

Pearl River Capital’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-327	Closed	-$21K	–	363
2018 Q4	$21K	Buy	+327	New	+$24.3K	0.1%	274

Other funds holding ANAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Pearl River Capital's ANAB Position: Q1 2019 in Review

Pearl River Capital sold out of AnaptysBio (ANAB) in Q1 2019, closing a stake of 327 shares — an estimated $21K sold.

Pearl River Capital first reported a position in ANAB in Q4 2018 and held it in 1 quarter. The position peaked at $21K in Q4 2018. 129 funds tracked by Wall St. Rank hold ANAB as of Q1 2019.

Pearl River Capital reported no remaining AnaptysBio position as of Q1 2019 after selling out during the quarter.
Pearl River Capital sold 327 AnaptysBio shares in Q1 2019, an estimated $21K.
Pearl River Capital first reported a position in AnaptysBio in Q4 2018 and held it in 1 quarter.
Pearl River Capital's AnaptysBio position peaked at $21K in Q4 2018.
129 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.